Asian Pacific Journal of Cancer Prevention最新文献

{"title":"Factors Associated with Cancer Patients' Perception of Treatment Rights Based on Universal Health Coverage Rights in Buriram Province, Thailand: A Cross-Sectional Study.","authors":"Jarukit Yarasee, Nakarin Prasit, Surachai Phimha, Nuttaporn Nidthumsakul, Amphawan Nonthamat","doi":"10.31557/APJCP.2026.27.8.3105","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.8.3105","url":null,"abstract":"<p><strong>Background: </strong>Treatment rights awareness is crucial for cancer patients as it enables comprehensive access to medical services, from diagnosis to follow-up care. Lack of understanding of these rights may result in delayed treatment and impact quality of life. Moreover, rights awareness helps patients make more informed decisions about their treatment options. This study aimed to investigate factors associated with cancer patients' perception of treatment rights under the Universal Health Coverage scheme in Buriram Province, Thailand.</p><p><strong>Methods: </strong>This cross-sectional analytical research involved 522 cancer patients with Universal Health Coverage rights who received services at Nangrong Hospital and its seven network hospitals. Data was collected using questionnaires. The statistical analysis employed descriptive statistics and multiple logistic regression for inferential analysis.</p><p><strong>Results: </strong>The study found that the prevalence of high-level rights perception among cancer patients in Buriram Province, Thailand was 78.35% (95% CI: 0.74-0.81). Factors significantly associated with rights perception included: being female (AOR = 3.80, 95%CI: 2.28-6.52, p-value < 0.001), having family members with chronic diseases (AOR = 2.26, 95%CI: 1.20-4.26, p-value = 0.012), having high media literacy health literacy (AOR = 2.10, 95%CI: 1.21-3.63, p-value = 0.008), high perception of resource support (AOR = 3.66, 95%CI: 1.77-6.26, p-value < 0.001), high perception of personnel (AOR = 3.06, 95%CI: 1.61-5.83, p-value = 0.001), high perception of process (AOR = 2.38, 95%CI: 1.42-4.00, p-value = 0.001), and high perception of physical evidence (AOR = 2.22, 95%CI: 1.26-3.92, p-value = 0.006).</p><p><strong>Conclusions: </strong>Enhancing patients' awareness of treatment rights will increase access to quality services, reduce healthcare disparities, and promote quality of life for cancer patients in the study area.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 8","pages":"3105-3114"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148842202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Patients' and Families' Perceptions of Family Meetings in Oncology: A Qualitative Study.","authors":"Fadi Fayyad Fawaris, Rufaida Ibdah, Elham H Othman, Sobuh Abu Shanab, Jumana Yousef, Mahmoud Abunasser, Mohammad Farhan, Ahmad Abu Alfwares","doi":"10.31557/APJCP.2026.27.8.3123","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.8.3123","url":null,"abstract":"<p><p>Background: Communication in healthcare settings is vital for patient safety and quality of care, affecting outcomes including anxiety levels, satisfaction, and medication adherence. Aim: This study explored patients' and family members' perceptions of the family meeting process in inpatient palliative care. Methods: An exploratory qualitative study was conducted using semi-structured individual interviews with family members of seriously ill patients recruited purposively from a nonprofit community hospital. Interviews were conducted in person between July 2010 and March 2011. Data were analyzed using thematic analysis following phenomenological approach. Results: Twenty-four respondents provided 118 significant statements. Four main themes emerged: (1) the distinctiveness of family meetings, (2) the blind transition and family readiness, (3) the impact on decision-making process, and (4) setting expectations and clarifying care goals. Conclusion: Family members reported that discussions with the inpatient palliative care team resulted in improved communication and knowledge, which contributed to enhanced decision-making ability.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 8","pages":"3123-3129"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do Generic EGFR-TKIs Perform as Well as Innovators? Real-World Evidence from Gefitinib-Treated EGFR-Mutated NSCLC in Indonesia.","authors":"Fitri Nurhayati, Rizka Andalucia, Jarir Ath Thobari, Elisna Syahruddin, Yusi Anggriani","doi":"10.31557/APJCP.2026.27.8.2969","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.8.2969","url":null,"abstract":"<p><strong>Background: </strong>Gefitinib is standard first-line therapy for $EGFR$-mutated non-small cell lung cancer (NSCLC). Following Indonesia's 2020 transition to generic gefitinib in national procurement, real-world comparative data remain limited. This study compared clinical outcomes between innovator and generic gefitinib in Indonesian referral hospitals.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of adults with EGFR-mutated NSCLC receiving first-line innovator or generic gefitinib between 2019-2022 at national cancer center and national respiratory center. The effectiveness was evaluated using progression-free survival (PFS) estimated by Kaplan-Meier and compared with the log-rank test; hazard ratios (HRs) were derived from Cox regression. Adverse events (AEs) were abstracted from patients' medical records based on physicians' documentation in the clinical progress notes and analyzed using Mann-Whitney tests. Multivariable analyses were performed to evaluate the association between gefitinib type (generic vs. innovator) and clinical outcomes while adjusting for potential confounders, including demographics, smoking status, comorbidities, disease stage, ECOG performance status, radiotherapy history, COVID-19 history, mutation subtype, and hospital. The follow-up period was 18 months within a 4-year horizon.</p><p><strong>Result: </strong>A total of 192 patients met the inclusion criteria (innovator n = 124; generic n = 68). The median PFS was 12.2 months (95% CI, 8.7-15.7) in the innovator group and 16.4 months (95% CI, 13.7-19.1) in the generic group. Although the generic formulation demonstrated a numerically longer median PFS, the difference was not statistically significant (HR = 1.61, 95% CI, 0.98-2.63; p = 0.104). Multivariate analysis showed that no baseline variable was significantly associated with PFS after adjustment. Safety profiles were generally comparable, but dermatologic and gastrointestinal AEs occurred more frequently with the generic formulation, with significantly higher frequencies (rate-adjusted) of diarrhoea, paronychia, and stomatitis (p = 0.002, 0.011, and 0.001, respectively). Other AEs, including dyspepsia, alopecia, neuropathy, and AST/ALT elevation did not differ significantly between groups.</p><p><strong>Conclusion: </strong>The generic formulation demonstrated comparable efficacy to the innovator drug in terms of progression-free survival, although a higher incidence of certain mild-to-moderate adverse events was noted. These findings support the therapeutic use of the generic gefitinib with careful monitoring of tolerability.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 8","pages":"2969-2976"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148842062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological and Theoretical Considerations Regarding a Study on Cervical Cancer Screening Practices in Pakistan.","authors":"Muhammad Umair Ahmad, Fahd Niaz Shaikh, Taimor Mohammed Khan","doi":"10.31557/APJCP.2026.27.8.2747","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.8.2747","url":null,"abstract":"","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 8","pages":"2747-2748"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Absence of Germline BRCA1 and BRCA2 Copy Number Variations Among Breast Cancer Patients in the Three Southern Border Provinces of Thailand.","authors":"Panupong Sukpan, Natthapon Khongcharoen, Srila Samphao","doi":"10.31557/APJCP.2026.27.8.2811","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.8.2811","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to investigate germline CNVs in the BRCA1 and BRCA2 genes.</p><p><strong>Materials and methods: </strong>Reanalysis of whole-exome sequencing (WES) data from 140 breast cancer (BC) patients originating from Thailand's three southern border provinces was performed using the Genome Analysis Toolkit Germline Copy Number Variant (GATK-gCNV) bioinformatics pipeline. CNVs identified as positive by this pipeline were further validated through multiplex ligation-dependent probe amplification (MLPA).</p><p><strong>Results: </strong>A total of 140 individuals were diagnosed with epithelial BC. Among them, 72.86% self-identified as Muslim-Thai, while 27.14% were Buddhist-Thai. The majority of cases (60.71%) were diagnosed at or before the age of 50 years. Notably, 20% of the patients presented with triple-negative breast cancer (TNBC). All enrolled patients underwent germline CNV analysis for the BRCA1 and BRCA2 genes.</p><p><strong>Conclusion: </strong>This study represents the first and largest investigation of germline CNVs in the BRCA1 and BRCA2 genes within this population. The absence of germline CNVs in both BRCA1 and BRCA2 suggests that routine screening for such alterations may be unwarranted in this specific population group.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 8","pages":"2811-2816"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surveillance Strategies for Oral Potentially Malignant Disorders: A Comprehensive Review and Clinical Decision Tree.","authors":"Hamed Mortazavi, Abolfazl Beigzadeh Jalali","doi":"10.31557/APJCP.2026.27.8.2773","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.8.2773","url":null,"abstract":"<p><strong>Objective: </strong>Oral potentially malignant disorders are a group of oral mucosal conditions with a significant risk of transforming into oral squamous cell carcinoma. Early detection and proper follow-up are crucial in improving patient outcomes. This review consolidates evidence on the clinical features, malignant potential, treatment, and follow-up strategies for the four most common oral potentially malignant disorders: oral leukoplakia, proliferative verrucous leukoplakia, erythroplakia, and oral lichen planus. It also proposes a clinical decision tree for structured surveillance of these lesions.</p><p><strong>Methods: </strong>This review consolidates evidence on the clinical features, malignant potential, treatment, and follow-up strategies for the four most common oral potentially malignant disorders.</p><p><strong>Results: </strong>This review highlights the variability in follow-up recommendations and emphasizes the need for individualized, evidence-informed monitoring strategies.</p><p><strong>Conclusion: </strong>To the best of our knowledge, this is among the first structured attempts to present a comprehensive clinical decision tree to guide practitioners in the surveillance of OPMDs. The proposed model provides clinicians with a practical tool to minimize the risk of malignant progression. Nevertheless, despite a growing body of literature, standardized surveillance protocols are still lacking, and further longitudinal research is required.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 8","pages":"2773-2781"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148842162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the Prevalence of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Across Africa: A Systematic Review and Meta-Analysis.","authors":"Jean Paul Muambangu Milambo, Wilson Wezile Chitha","doi":"10.31557/APJCP.2026.27.8.2761","DOIUrl":"10.31557/APJCP.2026.27.8.2761","url":null,"abstract":"<p><strong>Background: </strong>BRCA1 and BRCA2 gene mutations are major contributors to hereditary breast and ovarian cancer syndrome (HBOC). While mutation prevalence has been well-characterized in high-income countries, African populations remain underrepresented in genomics cancer research. Accurate prevalence data are essential for informing targeted screening, counselling, and personalized treatment strategies across the continent.</p><p><strong>Objective: </strong>To systematically assess the prevalence and geographic distribution of pathogenic BRCA1 and BRCA2 mutations in African populations affected by HBOC, and identify opportunities to enhance genetic testing and clinical integration.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. PubMed, Scopus, Web of Science, and Embase were searched for studies published between January 2000 and June 2024. Studies were eligible if they reported germline BRCA1 or BRCA2 mutation data in African individuals with breast and/or ovarian cancer. Two reviewers independently screened studies, extracted data, and assessed methodological quality. Meta-analyses were performed using STATA 18 and RevMan, with fixed-effects models applied. Heterogeneity was evaluated using the I² statistic, and subgroup analyses were conducted based on gene type.</p><p><strong>Results: </strong>A total of 52 studies from 19 African countries were included. Most studies originated from Morocco (28.4%), Tunisia (18.9%), South Africa (14.7%), and Nigeria (11.6%). Cross-sectional designs were most common (68.4%). Sanger sequencing was used in 45.3% of studies, followed by next-generation sequencing (31.6%). The overall pooled prevalence of pathogenic BRCA1/2 mutations was 9.0% (95% CI: 7.7-10.4%). Subgroup analyses showed a higher prevalence for BRCA1 mutations (10.5%, 95% CI: 8.3-13.0%) compared to BRCA2 (5.5%, 95% CI: 4.9-6.1%). Over half of the studies did not distinguish between the two genes, highlighting a need for standardized gene-specific reporting.</p><p><strong>Conclusion: </strong>There is a significant burden of pathogenic BRCA mutations in African HBOC populations, particularly BRCA1. However, gaps in geographic coverage and inconsistent reporting suggest the true burden may be underestimated. Expanding access to genetic testing, improving reporting standards, and integrating hereditary cancer screening into public health strategies are critical steps to advance precision oncology across Africa.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 8","pages":"2761-2771"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148842194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Changing Cancer Landscape in Nepal: The Rise of Gastric Cancer.","authors":"Kanchan Thapa, Bishwanath Acharya, Gambhir Shrestha","doi":"10.31557/APJCP.2026.27.8.2749","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.8.2749","url":null,"abstract":"","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 8","pages":"2749-2751"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miR-1294 Upregulation as a Diagnostic Biomarker for Cholangiocarcinoma.","authors":"Kittiya Supradit, Teva Phanaksri, Sattrachai Prasopdee, Sithichoke Tangphatsornruang, Duangjai Sangsrakru, Kanokpan Wongprasert, Montinee Pholhelm, Kritiya Butthongkomvong, Jutharat Kulsantiwong, Anthicha Kunjantarachot, Veerachai Thitapakorn","doi":"10.31557/APJCP.2026.27.8.2871","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.8.2871","url":null,"abstract":"<p><strong>Objective: </strong>To investigate plasma miR-1294 levels in cholangiocarcinoma (CCA) patients compared with healthy individuals and Opisthorchis viverrini-infected subjects.</p><p><strong>Methods: </strong>To assess its potential as a plasma-based diagnostic biomarker, plasma samples were collected and total RNA was extracted from 15 healthy controls (HC), 12 O. viverrini (OV)-infected individuals, and 33 patients with CCA. miR-1294 expression was quantified using RT-qPCR (MiRXES).</p><p><strong>Results: </strong>Relative expression analysis demonstrated a significant upregulation of plasma miR-1294 in patients with CCA compared with both HC and OV groups (P < 0.0001). Receiver operating characteristic (ROC) curve analysis showed that miR-1294 discriminated CCA from non-CCA subjects, yielding an area under the curve (AUC) of 0.8676, with a specificity of 96.30% and a sensitivity of 63.64%.</p><p><strong>Conclusion: </strong>The upregulation of plasma miR-1294 was investigated in this study. Despite these promising findings, the moderate sensitivity suggests that miR-1294 alone may not be sufficient as a standalone diagnostic marker. Nevertheless, its high specificity and non-invasive detectability highlight its potential utility as a complementary biomarker, particularly in combination with other diagnostic indicators for improved detection of CCA.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 8","pages":"2871-2877"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Awareness in a High-Risk Indian Population: A Study on First-Degree Female Relatives.","authors":"Pratibha Kole, Abhishek Basu, Suman Dhabal","doi":"10.31557/APJCP.2026.27.8.2977","DOIUrl":"https://doi.org/10.31557/APJCP.2026.27.8.2977","url":null,"abstract":"<p><strong>Background: </strong>Female first-degree relatives of women diagnosed with breast cancer have higher risk of developing the disease. This study aims to estimate the awareness, heightened risk perception, and screening practices in this high-risk population of women.</p><p><strong>Methods: </strong>A cross-sectional study was undertaken from August 2023 to January 2024 in a tertiary cancer centre of Eastern India. First-degree female relatives of breast cancer patients, aged ≥18 years, who provided informed consent, were interviewed face-to-face using a pre-tested, semi-structured questionnaire, followed by data analysis.</p><p><strong>Results: </strong>Among 307 women enrolled, 109 (35.5%) participants perceived being at higher risk for developing breast cancer. While breast lump was the most commonly (93.8%) known warning sign, few acknowledged other signs. Only 42.3% and 26.7% respectively, knew that previous breast cancer diagnosis and having blood relation with the patient were known risk factors. Most were oblivious to other potential risks. Despite wide agreement (92.8%) on benefits of early detection, only 26.7% believed screening to be essential. Only 120 (39.1%) participants had ever performed a breast self-examination [BSE] (regular 5.9%) and 15 (4.9%) had ever undergone a clinical breast examination [CBE] (regular 0.3%). Only 32 (10.4%) had heard of mammography, and only 3 (0.9%) had ever undergone mammography. Logistic regression analysis predicted the likelihood of screening practices. Regarding diagnosis, only 18.6% knew that biopsy was the best method for confirmation. Regarding treatment, the majority were informed about chemotherapy (91.86%), surgery (91.2%) and radiotherapy (64.2%) but few knew about hormonal therapy (14%) and targeted therapy (0.98%). Composite awareness score (0-37) was calculated where only 3.3% were high scores (25-37), mostly urban graduates.</p><p><strong>Conclusion: </strong>Our study exposes the lack of awareness regarding breast cancer risks and prevention among this high-risk group of Indian women. Focused interventions in health policy need to be strategized to mitigate this problem.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 8","pages":"2977-2988"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}